Improved sample introduction approach in hydrophilic interaction liquid chromatography to avoid breakthrough of proteins
Metadata
Show full item recordAuthor
Pérez Robles, Raquel; Fekete, Szabolcs; Kormány, Róbert; Navas Iglesias, Natalia Africa; Guillarme, DavyEditorial
Elsevier
Materia
Hydrophilic interaction liquid chromatography Breakthrough Solvent mismatch
Date
2024Referencia bibliográfica
Journal of Chromatography A 1713 (2024) 464498 [10.1016/j.chroma.2023.464498]
Sponsorship
Junta de Andalucía (ref: DOC_01694)Abstract
When therapeutic proteins are analysed under hydrophilic interaction liquid chromatography (HILIC) conditions,
there is an inherent mismatch between the sample diluent (proteins must be solubilised in aqueous media)
and the mobile phase, which is mostly composed of aprotic solvent (acetonitrile). This difference in eluent
strength between sample diluent and mobile phase is responsible for severe analyte breakthrough and peak
distortion. As demonstrated with therapeutic proteins of different sizes (insulin of 6 kDa, anakinra of 17 kDa and
rituximab subunits of 25 and 50 kDa), only very small volumes of 0.1–0.2 μL can be injected without breakthrough
effects, when performing rapid analysis on short HILIC columns of 20–50 mm, leading to poor sensitivity.
In order to avoid the undesired effect of the strong sample diluent, a special injection program should be
preferred. This consists in the addition and automatic injection of a defined volume of weak solvent (acetonitrile)
along with the sample to increase retention factors during sample loading. Various injection programs were
tested, including the addition of a pre-injection or post-injection or both (bracketed injection) of acetonitrile
plugs. Several weak to strong injection solvent ratios of 1:1, 1:2, 1:4 and 1:10 were tested. Our work proves that
the addition of a pre-plug solvent with a weak vs. strong injection solvent ratio of 1:10 is a valuable strategy to
inject relatively large volumes of proteins in HILIC, regardless of column dimensions, thus maximising sensitivity.
No peak deformation or breakthrough was observed under these conditions. However, it is important to
note that peak broadening (40 % larger peaks) was observed when the injection program increased the injection
solvent ratio from 1:1 to 1:10. Finally, this strategy was applied to a wide range of therapeutic mAb products
with different physico-chemical properties. In all cases, relatively large volumes can be successfully injected onto
small volume HILIC columns using a purely aqueous sample diluent, as long as an appropriate (weak) solvent
pre-injection is applied.